Overview
On April 13, 2026, the U.S. Food and Drug Administration (FDA) reminded over 2,200 clinical trial sponsors and researchers of their legal duty to submit results to ClinicalTrials.gov. Compliance is mandatory, and ignoring it can be costly.
A Persistent Problem: Missing Trial Results
Despite regulations, the FDA found that 29.6% of studies that were likely required to report results have no results posted to ClinicalTrials.gov.
These missing results typically involve:
- Interventional studies
- Trials with a U.S. nexus
- Studies involving FDA-regulated products
- Trials past their reporting deadlines
Notably, these figures exclude Phase 1 trials and device feasibility studies.
The implications are serious. When trial results, especially negative or inconclusive ones, are not disclosed, the public record becomes incomplete and biased. It overrepresents success and underreports risks or inefficacy.
The Risk of Publication Bias
The FDA highlighted a critical issue:
Sponsors’ failure to report all results, particularly negative outcomes, skews the evidence base and distorts perceptions of medical products.
This leads to:
- Overrepresentation of successful outcomes
- Underreporting of risks or lack of efficacy
- Distorted perceptions of medical products
Former FDA Commissioner, Marty Makary, emphasized the ethical dimension:
“Those sponsoring clinical trials have an ethical obligation to make results public regardless of the data’s influence on the company’s share price.”
For clinicians, this lack of transparency can directly impact patient care decisions:
“If you are a doctor deciding whether or not to prescribe a medication… you deserve to have the best data.”
Increased FDA Enforcement Activity
The FDA is escalating compliance efforts, not just issuing reminders.
On March 30, 2026, the agency:
- Contacted over 2,200 organizations and investigators
- Flagged more than 3,000 clinical trials
- Identified missing results or incomplete quality review submissions
These communications are part of a broader risk-based enforcement strategy, which may include:
- Pre-notices of noncompliance
- Notices of Noncompliance
- Potential regulatory actions if issues remain unresolved
The outreach is a chance for voluntary compliance and a sign that stricter enforcement is coming.
Why This Matters Now
The FDA’s action highlights increasing urgency in clinical research. Expectations for transparency are rising, regulatory scrutiny is increasing, and the risks of noncompliance, including financial penalties and reputational damage, are growing.
As Tracy Beth Hoeg, Acting Director of CDER, stated:
“We hope that the thousands of messages… will improve patient safety and keep researchers and the public better informed.”
Take immediate action: review and update your ClinicalTrials.gov records to ensure they are accurate and fully compliant now.
The Compliance Challenge
Meeting ClinicalTrials.gov requirements is sometimes complex.
Common challenges include:
- Understanding applicability under the FDAAA Final Rule
- Navigating the Protocol Registration and Results System (PRS)
- Ensuring accurate and timely data entry
- Responding to quality control (QC) review comments
- Managing updates throughout the study lifecycle
Without immediate robust training, these tasks can cause delays, errors, and increase compliance risk.
The Role of Training in Achieving Compliance
Given the complex, changing enforcement landscape, targeted training is essential. Fortunately, CITI Program offers two training options.
Principal Investigator’s Guide to ClinicalTrials.gov – This video-based course is designed specifically for investigators who need practical, actionable guidance.
Key benefits:
- Step-by-step instructions on using the PRS system
- Guidance on managing trial records from start to finish
- Strategies for responding to QC feedback effectively
- Ongoing compliance support throughout the study lifecycle
This course helps investigators manage responsibilities and avoid common mistakes.
Protocol Registration and Results Summary Disclosure in ClinicalTrials.gov – This video-enhanced course provides research administrators and investigators with a deep dive into regulatory requirements.
Key benefits:
- Clear explanation of the FDAAA Final Rule and NIH Policy
- Step-by-step walkthrough of data entry and submission processes
- Practical guidance to reduce the risk of:
- Civil monetary penalties
- Loss of NIH grant funding
This training lowers compliance risk and boosts efficiency for organizations.
A Call to Action for Sponsors and Investigators
The FDA’s reminder is more than notice—it’s a warning.
Organizations should act immediately to:
- Audit current trial records on ClinicalTrials.gov.
- Identify missing or incomplete results submissions.
- Address QC review issues promptly.
- Invest in targeted training for research teams.
Final Thoughts
Clinical trial transparency is essential for scientific integrity and patient safety. The FDA’s action highlights both a critical gap and an opportunity.
By prioritizing compliance and investing in the right training, research administrators and investigators can:
- Strengthen trust with regulators and the public.
- Avoid enforcement actions and financial penalties.
- Contribute to a more accurate and complete scientific record.
The message is clear. Compliance is not optional, it’s a responsibility.
